EN 
FR | Discovery | Proof of Concept | Pre-Clinical |
|---|
Pipeline Progression
CAR-HSC
Pre-B Acute Lymphoblastic Leukemia (CD22)
CAR-HSC
Rhabdomyosarcoma (B7-H3)
CAR-HSC
Undisclosed indication (B7-H3)
CAR-HSC
Glioblastoma (EGFRvIII)
In Vivo CAR Delivery
Our immunotherapy development programs
Precursor-B Acute Lymphoblastic Leukemia
(Pre-B ALL)
Pre-B ALL is the most common malignancy in childhood with an overall cure rate of approximately 85%. However, relapsed ALL have an event-free survival of only 47%. CAR-T cells were shown efficient in ALL, but as much as 30 to 60% of patients relapse mainly because of the lack of CAR-T cells persistence or antigen loss (CD19).
Also, CRS occurs in 75% to 100% of children treated by CAR-T cells, with between 16% to 46% of patient needing hospitalisation. There is, therefore, a dire need to improve CAR-therapy for children with ALL.
Our immunotherapy
development programs
Precursor-B Acute Lymphoblastic Leukemia
(Pre-B ALL)
Pre-B ALL is the most common malignancy in childhood with an overall cure rate of approximately 85%. However, relapsed ALL have an event-free survival of only 47%. CAR-T cells were shown efficient in ALL, but as much as 30 to 60% of patients relapse mainly because of the lack of CAR-T cells persistence or antigen loss (CD19).
Also, CRS occurs in 75% to 100% of children treated by CAR-T cells, with between 16% to 46% of patient needing hospitalisation. There is, therefore, a dire need to improve CAR-therapy for children with ALL.
Rhabdomyosarcoma (RMS)
Although rare (4.3 per 106 <20 years old/year), RMS is the most common soft-tissue sarcoma in childhood. Although progress in treatment has led to a remission rate of ~ 60% of pediatric cases, high-risk RMS patients still have a poor prognosis, and survivors have lifetime consequences from the treatments.
There has been no significant progress in the treatment of this disease in the last 5 decades. Hence, efficient immunotherapy for RMS needs to be developed, and stem-cell based CAR therapy represents a great hope.
Glioblastoma (GBM)
GBM is the most common form of brain cancer, with an average annual incidence of 3.21 per 100,000 people in the US. It is also the most aggressive form of brain tumor, with a 10-year survival rate of approximately 1%. This highlights the urgent need for innovative therapies.
At Immugenia, we are pioneering a stem-cell-based CAR-T therapy that could offer a breakthrough in immunotherapy for GBM by combining both CAR-T and CAR-NK cells in one treatment for their synergistic activity against cancer, as nature intended.
Rhabdomyosarcoma (RMS)
Although rare (4.3 per 106 <20 years old/year), RMS is the most common soft-tissue sarcoma in childhood. Although progress in treatment has led to a remission rate of ~ 60% of pediatric cases, high-risk RMS patients still have a poor prognosis, and survivors have lifetime consequences from the treatments.
There has been no significant progress in the treatment of this disease in the last 5 decades. Hence, efficient immunotherapy for RMS needs to be developed, and stem-cell based CAR therapy represents a great hope.
Glioblastoma (GBM)
GBM is the most common form of brain cancer, with an average annual incidence of 3.21 per 100,000 people in the US. It is also the most aggressive form of brain tumor, with a 10-year survival rate of approximately 1%. This highlights the urgent need for innovative therapies.
At Immugenia, we are pioneering a stem-cell-based CAR-T therapy that could offer a breakthrough in immunotherapy for GBM by combining both CAR-T and CAR-NK cells in one treatment for their synergistic activity against cancer, as nature intended.
1 The American Childhood Cancer Organization 2022, accessed 5 April 2022, <https://www.acco.org/>
2CureSearch for Children’s Cancer 2022, accessed 12 April 2022, <https://curesearch.org/>
